Cargando…

Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops

OBJECTIVES: To assess phosphate and osmolarity levels of chronically administered eye drops commercially available in Turkey. MATERIALS AND METHODS: A total of 53 topical eye drops including 18 antiglaucoma drugs, 4 nonsteroidal anti-inflammatory drugs (NSAIDs), 10 corticosteroids, 7 antihistaminics...

Descripción completa

Detalles Bibliográficos
Autores principales: Özalp, Onur, Atalay, Eray, Alataş, İbrahim Özkan, Küskü Kiraz, Zeynep, Yıldırım, Nilgün
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624467/
https://www.ncbi.nlm.nih.gov/pubmed/31245971
http://dx.doi.org/10.4274/tjo.galenos.2018.43827
_version_ 1783434268074049536
author Özalp, Onur
Atalay, Eray
Alataş, İbrahim Özkan
Küskü Kiraz, Zeynep
Yıldırım, Nilgün
author_facet Özalp, Onur
Atalay, Eray
Alataş, İbrahim Özkan
Küskü Kiraz, Zeynep
Yıldırım, Nilgün
author_sort Özalp, Onur
collection PubMed
description OBJECTIVES: To assess phosphate and osmolarity levels of chronically administered eye drops commercially available in Turkey. MATERIALS AND METHODS: A total of 53 topical eye drops including 18 antiglaucoma drugs, 4 nonsteroidal anti-inflammatory drugs (NSAIDs), 10 corticosteroids, 7 antihistaminics, and 14 artificial tears identified using the Vademecum Modern Medications Guideline (2018) were included in the study. Phosphate levels were assessed using Roche Cobas C501 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) and the respective kits. Osmolarity was assessed using Vescor Vapro 5600 vapor pressure osmometer (Sanova Medical Systems, Vienna, Austria). Mean phosphate and osmolarity levels were obtained after averaging three measurements. Eye drops were categorized as isoosmolar, hypoosmolar and hyperosmolar based on physiologic tear osmolarity range (296.5±9.8 mOsm/L). RESULTS: The highest phosphate concentration was found in the antiglaucoma group (20.3±35.4 mmol/L), followed by antihistaminics (17.3±17.9 mmol/L), corticosteroids (15.2±19.1 mmol/L), artificial tears (0.8±1.0), and NSAIDs (0.04±0.08). Percentage of medications in the hyperosmolar category was highest in the NSAI group (75%), followed by antihistaminics (43%), corticosteroids (20%), and antiglaucoma drugs (19%). Nearly all of the artificial tear formulations were in the hypoosmolar (71%) or isoosmolar (21%) categories. CONCLUSION: Approximately 40% of glaucoma medications and approximately 60% of corticosteroid and antihistaminic medications had a phosphate concentration higher than the physiologic tear phosphate level (1.45 mmol/L).
format Online
Article
Text
id pubmed-6624467
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-66244672019-07-17 Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops Özalp, Onur Atalay, Eray Alataş, İbrahim Özkan Küskü Kiraz, Zeynep Yıldırım, Nilgün Turk J Ophthalmol Original Article OBJECTIVES: To assess phosphate and osmolarity levels of chronically administered eye drops commercially available in Turkey. MATERIALS AND METHODS: A total of 53 topical eye drops including 18 antiglaucoma drugs, 4 nonsteroidal anti-inflammatory drugs (NSAIDs), 10 corticosteroids, 7 antihistaminics, and 14 artificial tears identified using the Vademecum Modern Medications Guideline (2018) were included in the study. Phosphate levels were assessed using Roche Cobas C501 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) and the respective kits. Osmolarity was assessed using Vescor Vapro 5600 vapor pressure osmometer (Sanova Medical Systems, Vienna, Austria). Mean phosphate and osmolarity levels were obtained after averaging three measurements. Eye drops were categorized as isoosmolar, hypoosmolar and hyperosmolar based on physiologic tear osmolarity range (296.5±9.8 mOsm/L). RESULTS: The highest phosphate concentration was found in the antiglaucoma group (20.3±35.4 mmol/L), followed by antihistaminics (17.3±17.9 mmol/L), corticosteroids (15.2±19.1 mmol/L), artificial tears (0.8±1.0), and NSAIDs (0.04±0.08). Percentage of medications in the hyperosmolar category was highest in the NSAI group (75%), followed by antihistaminics (43%), corticosteroids (20%), and antiglaucoma drugs (19%). Nearly all of the artificial tear formulations were in the hypoosmolar (71%) or isoosmolar (21%) categories. CONCLUSION: Approximately 40% of glaucoma medications and approximately 60% of corticosteroid and antihistaminic medications had a phosphate concentration higher than the physiologic tear phosphate level (1.45 mmol/L). Galenos Publishing 2019-06 2019-06-27 /pmc/articles/PMC6624467/ /pubmed/31245971 http://dx.doi.org/10.4274/tjo.galenos.2018.43827 Text en © Copyright 2019 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Özalp, Onur
Atalay, Eray
Alataş, İbrahim Özkan
Küskü Kiraz, Zeynep
Yıldırım, Nilgün
Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title_full Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title_fullStr Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title_full_unstemmed Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title_short Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops
title_sort assessment of phosphate and osmolarity levels in chronically administered eye drops
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624467/
https://www.ncbi.nlm.nih.gov/pubmed/31245971
http://dx.doi.org/10.4274/tjo.galenos.2018.43827
work_keys_str_mv AT ozalponur assessmentofphosphateandosmolaritylevelsinchronicallyadministeredeyedrops
AT atalayeray assessmentofphosphateandosmolaritylevelsinchronicallyadministeredeyedrops
AT alatasibrahimozkan assessmentofphosphateandosmolaritylevelsinchronicallyadministeredeyedrops
AT kuskukirazzeynep assessmentofphosphateandosmolaritylevelsinchronicallyadministeredeyedrops
AT yıldırımnilgun assessmentofphosphateandosmolaritylevelsinchronicallyadministeredeyedrops